BR0309747A - Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial - Google Patents
Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelialInfo
- Publication number
- BR0309747A BR0309747A BR0309747-1A BR0309747A BR0309747A BR 0309747 A BR0309747 A BR 0309747A BR 0309747 A BR0309747 A BR 0309747A BR 0309747 A BR0309747 A BR 0309747A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- vascular
- growth factor
- mediated
- endothelial
- Prior art date
Links
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 208000019553 vascular disease Diseases 0.000 title abstract 3
- 239000003102 growth factor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000006444 vascular growth Effects 0.000 title abstract 2
- 230000003511 endothelial effect Effects 0.000 title 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 abstract 1
- 229950008930 amfenac Drugs 0.000 abstract 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 abstract 1
- 229960001002 nepafenac Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37742902P | 2002-05-03 | 2002-05-03 | |
| PCT/US2003/011769 WO2003092669A2 (en) | 2002-05-03 | 2003-04-16 | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309747A true BR0309747A (pt) | 2005-04-26 |
Family
ID=29401494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0309747-1A BR0309747A (pt) | 2002-05-03 | 2003-04-16 | Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050143468A1 (https=) |
| EP (1) | EP1507522A2 (https=) |
| JP (1) | JP2005525408A (https=) |
| KR (1) | KR20040101499A (https=) |
| CN (1) | CN1649575A (https=) |
| AU (1) | AU2003231730A1 (https=) |
| BR (1) | BR0309747A (https=) |
| CA (1) | CA2483275A1 (https=) |
| MX (1) | MXPA04010132A (https=) |
| PL (1) | PL373787A1 (https=) |
| WO (1) | WO2003092669A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060142236A1 (en) * | 1994-05-31 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US20090087424A1 (en) * | 2004-11-26 | 2009-04-02 | Noriko Miyamoto | Modulating Retinal Pigmented Epithelium Permeaion By Inhibiting Or Activating VEGFR-1 |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| HRP20100559T1 (hr) * | 2005-11-29 | 2010-11-30 | Glaxosmithkline Llc | Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule |
| JP2012062258A (ja) * | 2010-09-14 | 2012-03-29 | Oriza Yuka Kk | 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤 |
| TW202023575A (zh) * | 2011-09-16 | 2020-07-01 | 美商遠景生物製藥股份有限公司 | 安定之普維酮—碘組成物 |
| JP6427843B2 (ja) * | 2013-03-29 | 2018-11-28 | 株式会社ＡｓｋＡｔ | 眼疾患治療剤 |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE400966B (sv) * | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
| US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| US4254146A (en) * | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
| US4503073A (en) * | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
| US4568695A (en) * | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
| US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
| CA1325382C (en) * | 1988-01-27 | 1993-12-21 | Takahiro Ogawa | Locally administrable therapeutic composition for inflammatory disease |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| AU782386C (en) * | 1999-08-31 | 2006-08-10 | Brigham And Women's Hospital | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
| AU2002247284A1 (en) * | 2001-04-02 | 2002-10-15 | Alcon, Inc. | Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac |
-
2003
- 2003-04-16 BR BR0309747-1A patent/BR0309747A/pt not_active Application Discontinuation
- 2003-04-16 AU AU2003231730A patent/AU2003231730A1/en not_active Abandoned
- 2003-04-16 CN CNA038094797A patent/CN1649575A/zh active Pending
- 2003-04-16 KR KR10-2004-7016542A patent/KR20040101499A/ko not_active Withdrawn
- 2003-04-16 CA CA002483275A patent/CA2483275A1/en not_active Abandoned
- 2003-04-16 MX MXPA04010132A patent/MXPA04010132A/es unknown
- 2003-04-16 WO PCT/US2003/011769 patent/WO2003092669A2/en not_active Ceased
- 2003-04-16 PL PL03373787A patent/PL373787A1/xx not_active Application Discontinuation
- 2003-04-16 EP EP03747593A patent/EP1507522A2/en not_active Withdrawn
- 2003-04-16 JP JP2004500853A patent/JP2005525408A/ja active Pending
- 2003-04-16 US US10/511,414 patent/US20050143468A1/en not_active Abandoned
- 2003-04-16 US US10/417,466 patent/US20030207941A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1507522A2 (en) | 2005-02-23 |
| WO2003092669A2 (en) | 2003-11-13 |
| US20050143468A1 (en) | 2005-06-30 |
| JP2005525408A (ja) | 2005-08-25 |
| PL373787A1 (en) | 2005-09-19 |
| CA2483275A1 (en) | 2003-11-13 |
| US20030207941A1 (en) | 2003-11-06 |
| AU2003231730A1 (en) | 2003-11-17 |
| MXPA04010132A (es) | 2005-01-25 |
| CN1649575A (zh) | 2005-08-03 |
| KR20040101499A (ko) | 2004-12-02 |
| WO2003092669A3 (en) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| BR9909795A (pt) | Derivados de epotilona 12, 13-modificados | |
| AP2001002217A0 (en) | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. | |
| DE60327745D1 (de) | Verwendung von adapalen zur behandlung dermatologischer erkrankungen | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| BRPI0407993B8 (pt) | compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos | |
| BRPI0307351B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
| WO2003080582A3 (de) | Fredericamycin-derivate | |
| EP1251126A3 (en) | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | |
| DE60336664D1 (de) | Nichtnukleosidische reverse-transkriptase-hemmer | |
| DK1311256T3 (da) | Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| BRPI0508137A (pt) | composição de tratamento dos cabelos, método de alisamento de cabelos e uso da composição | |
| EA200301276A1 (ru) | Новые производные сульфоновых кислот | |
| ATE316962T1 (de) | Pyrimidin-derivate als selective inhibitoren von cox-2 | |
| BR9807145A (pt) | 2-metoxiimino-2-(piridiniloximetil) fenilacetamidas com derivados de ácido carboxìlico no anel de piridina como fungicidas. | |
| BR0309747A (pt) | Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial | |
| DE60015508T2 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| CY1107158T1 (el) | Νεα παραγωγα της ισοκινολινης, η μεθοδος παρασκευης τους και η χρηση τους για τη θεραπεια των διαταραχων του μελατονινεργικου συστηματος | |
| EE05241B1 (et) | Distamtsiini a-halogenoakrlolderivaadi kasutamine | |
| CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |